| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3947899 | Gynecologic Oncology | 2006 | 8 Pages |
Abstract
Our pilot study demonstrates that P-gp expression may be a reliable independent prognostic factor of survival in patients with ovarian serous carcinoma. Moreover, P-gp immunostaining may be useful for dividing ovarian carcinoma patients into chemoresponsive and chemoresistant groups.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Evgeny Yakirevich, Edmond Sabo, Inna Naroditsky, Yanina Sova, Ofer Lavie, Murray B. Resnick,